• Feb 18, 2025

1 Industrials Stock to Add to Your Roster and 2 to Ignore

Industrials businesses quietly power the physical things we depend on, from cars and homes to e-commerce infrastructure. Unfortunately, this role also comes with a demand profile tethered to the ebbs and flows of the broader economy, and the industry is currently lagging as its six-month return of 6% has trailed the S&P 500’s 9.3% gain.

  • Feb 18, 2025

Great Lakes Dredge & Dock (NASDAQ:GLDD) Misses Q4 Revenue Estimates

Dredging and coastal protection company Great Lakes Dredge & Dock (NASDAQ:GLDD) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 11.6% year on year to $202.8 million. Its GAAP profit of $0.29 per share was 27.9% above analysts’ consensus estimates.

  • Feb 18, 2025

3 Industrials Stocks to Axe From Your List

Whether you see them or not, industrials businesses play a crucial part in our daily activities. But they are at the whim of volatile macroeconomic factors that influence capital spending (like interest rates), and the industry has underperformed the market over the past six months as its 5.9% return lagged the S&P 500 by 3.5 percentage points.

  • Feb 18, 2025

Leftist’s Flop in Colombia Sparks Wild Election-Bet Stock Rally

(Bloomberg) -- It’s been an unusual start to the year for Colombian stocks.Most Read from BloombergWhy Barcelona Bought the Building That Symbolizes Its Housing CrisisPor qué Barcelona compró el edificio que simboliza su crisis inmobiliariaA Filmmaker’s Surreal Journey Into His Own Private WinnipegTrump Child Refugee Agency Shares Data With Immigration EnforcersNYC Restaurants Are Still Waiting for Their Outdoor Dining Plans to Be ApprovedFor one, the market is way up — some 21% in dollar terms,

  • Feb 18, 2025

Hillman (NASDAQ:HLMN) Misses Q4 Sales Targets

Hardware products and merchandising solutions provider Hillman (NASDAQ:HLMN) missed Wall Street’s revenue expectations in Q4 CY2024, with sales flat year on year at $349.6 million. On the other hand, the company’s outlook for the full year was close to analysts’ estimates with revenue guided to $1.54 billion at the midpoint. Its non-GAAP profit of $0.10 per share was in line with analysts’ consensus estimates.

  • Feb 18, 2025

NeoGenomics (NASDAQ:NEO) Misses Q4 Sales Targets

Oncology (cancer) diagnostics company NeoGenomics (NASDAQ:NEO) missed Wall Street’s revenue expectations in Q4 CY2024, but sales rose 10.6% year on year to $172 million. On the other hand, the company’s full-year revenue guidance of $740 million at the midpoint came in 0.7% above analysts’ estimates. Its non-GAAP profit of $0.04 per share was $0.01 above analysts’ consensus estimates.